Q-omics provides the consensus-scored ZAR1L profile across patient tissues and cancer cell-line models. ZAR1L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ZAR1L is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, ZAR1L RNA expression shows 9,502 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, LUAD, and TGCT as cancer lineages where ZAR1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZAR1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZAR1L survival associations across molecular data types. ZAR1L RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZAR1L RNA expression–survival associations across cancer types. High ZAR1L expression shows unfavorable associations in KICH, MESO, KIRC and LIHC, but favorable associations in DLBC and SKCM. The DLBC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for ZAR1L RNA expression.
This table summarizes ZAR1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZAR1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZAR1L shows lower tumor expression in KICH and THCA and higher tumor expression in LUAD, BLCA, LUSC and LIHC. The LUAD box plot shows higher ZAR1L RNA expression in tumor versus normal tissue (log2 FC = +0.111, t-test p < 0.001).
This table shows molecular features associated with ZAR1L in patient tissues and cancer cell lines. In patient samples, ZAR1L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZAR1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
